5-[4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]benzyl]-2,4-thiazolidinedione | 194713-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 5-[4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]benzyl]-2,4-thiazolidinedione
• 英文别名: 5-[[4-[2-(4-oxo-2H-1,3-benzoxazin-3-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 194713-46-7
• 化学式: C₂₀H₁₈N₂O₅S
• 分子量: 398.439
• InChiKey: RFMNEXVCPAPDRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Benzoazine derivative or salt thereof and pharmaceutical composition comprising the same
  申请人：SS Pharmaceutical Co., Ltd.

  公开号：EP0787727A1

  公开（公告）日：1997-08-06

  A benzoazine derivative represented by the following formula (1),    wherein R1 represents an alkyl group, alkoxy group, halogen atom, halogenoalkyl group, amino group, hydroxy group, benzyloxy group which may have a substituent, cyano group, carbamoyl group, acyl group, nitro group, carboxy group, or sulfonamide group; R2 and R3 may be the same or different and each individually represents a hydrogen atom or an alkyl group, or R2 and R3 indicate in combination an alkylene group having 2-7 carbon atoms; R4 and R5 may be the same or different and each individually represents a hydrogen atom or an alkyl group; X denotes O, S, or N-R6 (wherein R6 represents a hydrogen atom, an alkyl group, or an aryl group or pyridyl group which may have a substituent); m is an integer from 0 to 4; and n is an integer from l to 3, or a salt of the benzoazine derivative. The compound exhibits superior effects for reducing blood glucose value, plasma insulin value, and plasma triglyceride value, and is useful as a medicament for preventing or treating diabetes, hyperlipidemia, and obesity.

  由下式(1)代表的苯并嗪衍生物、 其中 R1 代表烷基、烷氧基、卤素原子、卤代烷基、氨基、羟基、可能具有取代基的苄氧基、氰基、氨基甲酰基、酰基、硝基、羧基或磺酰胺基；R2 和 R3 可以相同或不同，各自单独代表氢原子或烷基，或 R2 和 R3 组合表示具有 2-7 个碳原子的亚烷基；R4和R5可以相同或不同，各自代表氢原子或烷基；X表示O、S或N-R6（其中R6代表氢原子、烷基或芳基或吡啶基，可具有取代基）；m是0至4的整数；n是l至3的整数，或苯并嗪衍生物的盐。该化合物在降低血糖值、血浆胰岛素值和血浆甘油三酯值方面表现出卓越的效果，可用作预防或治疗糖尿病、高脂血症和肥胖症的药物。
• PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS
  申请人：University of Fukui

  公开号：EP3733203A1

  公开（公告）日：2020-11-04

  Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

  本发明提供了预防和治疗白内障的药剂，其作用机理与传统药剂不同，还提供了使用 PPAR 激活剂生产此类药剂的方法。一种用于预防和/或治疗白内障的药剂含有 PPAR 激活剂作为活性成分。
• Alpha-Substituted phenylpropionic acid derivative and medicine containing the same
  申请人：SSP Co., Ltd.

  公开号：EP0903343B1

  公开（公告）日：2003-05-28
• [EN] PPAR-ALPHA AGONISTS FOR TREATING MITOCHONDRIAL DISEASES<br/>[FR] AGONISTES DU RÉCEPTEUR PPAR-ALPHA POUR LE TRAITEMENT DE MALADIES MITOCHONDRIALES
  申请人：MITOBRIDGE INC

  公开号：WO2017044551A1

  公开（公告）日：2017-03-16

  Provided herein are methods for increasing PPARalpha activity and methods for treating PPARalpha related diseases (e.g., mitochondrial diseases).